scispace - formally typeset
Search or ask a question

Showing papers by "Monica Bellei published in 2014"


Journal ArticleDOI
TL;DR: Combined-modality treatment resulted in fewer early progressions in clinical stage I/II HL, although early outcome was excellent in both arms.
Abstract: Purpose Combined-modality treatment is standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL). We hypothesized that an early positron emission tomography (PET) scan could be used to adapt treatment. Therefore, we started the randomized EORTC/LYSA/FIL Intergroup H10 trial evaluating whether involved-node radiotherapy (IN-RT) could be omitted without compromising progression-free survival in patients attaining a negative early PET scan after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as compared with standard combined-modality treatment.

319 citations